KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Tax ProvisionsTax Rate
Others
Ratios

BioNTech SE (BNTX) EBITDA (2018 - 2025)

Historic EBITDA for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to -$54.8 million.

  • BioNTech SE's EBITDA fell 57547.68% to -$54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year decrease of 111.18%. This contributed to the annual value of -$1.4 billion for FY2024, which is 28906.84% down from last year.
  • BioNTech SE's EBITDA amounted to -$54.8 million in Q3 2025, which was down 57547.68% from -$567.2 million recorded in Q2 2025.
  • BioNTech SE's EBITDA's 5-year high stood at $5.6 billion during Q3 2021, with a 5-year trough of -$1.0 billion in Q2 2024.
  • In the last 5 years, BioNTech SE's EBITDA had a median value of $158.8 million in 2024 and averaged $1.3 billion.
  • As far as peak fluctuations go, BioNTech SE's EBITDA surged by 2.558385934074928e17% in 2021, and later crashed by 57547.68% in 2025.
  • Over the past 5 years, BioNTech SE's EBITDA (Quarter) stood at $5376.3 in 2021, then skyrocketed by 62488213.64% to $3.4 billion in 2022, then crashed by 83.15% to $566.2 million in 2023, then tumbled by 71.95% to $158.8 million in 2024, then plummeted by 134.53% to -$54.8 million in 2025.
  • Its last three reported values are -$54.8 million in Q3 2025, -$567.2 million for Q2 2025, and -$561.8 million during Q1 2025.